These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23480233)

  • 1. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).
    Bouamar R; Shuker N; Hesselink DA; Weimar W; Ekberg H; Kaplan B; Bernasconi C; van Gelder T
    Am J Transplant; 2013 May; 13(5):1253-61. PubMed ID: 23480233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.
    Egeland EJ; Robertsen I; Hermann M; Midtvedt K; Størset E; Gustavsen MT; Reisæter AV; Klaasen R; Bergan S; Holdaas H; Hartmann A; Åsberg A
    Transplantation; 2017 Aug; 101(8):e273-e279. PubMed ID: 28452920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Ther Drug Monit; 2019 Aug; 41(4):528-532. PubMed ID: 31259882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation.
    Ding CG; Jiao LZ; Han F; Xiang HL; Tian PX; Ding XM; Pan XM; Tian XH; Li Y; Zheng J; Xue WJ
    Chin Med J (Engl); 2018 Jun; 131(11):1302-1307. PubMed ID: 29786042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients.
    Richards KR; Hager D; Muth B; Astor BC; Kaufman D; Djamali A
    Transplantation; 2014 May; 97(10):986-91. PubMed ID: 24784360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
    Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
    Charpentier B; Rostaing L; Berthoux F; Lang P; Civati G; Touraine JL; Squifflet JP; Vialtel P; Abramowicz D; Mourad G; Wolf P; Cassuto E; Moulin B; Rifle G; Pruna A; Merville P; Mignon F; Legendre C; Le Pogamp P; Lebranchu Y; Toupance O; Hurault De Ligny B; Touchard G; Olmer M; Purgus R; Pouteil-Noble C; Glotz D; Bourbigot B; Leski M; Wauters JP; Kessler M
    Transplantation; 2003 Mar; 75(6):844-51. PubMed ID: 12660513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Rejection in Kidney Transplantation and Early Beginning of Tacrolimus.
    Salcedo-Herrera S; Pinto Ramirez JL; García-Lopez A; Amaya-Nieto J; Girón-Luque F
    Transplant Proc; 2019; 51(6):1758-1762. PubMed ID: 31399163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
    Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
    Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.